Drugs Containing Excipient (Inactive Ingredient) SILICA

« Back to Dashboard

Branded drugs containing SILICA excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	LOREEV XR	lorazepam	50090-7592	SILICA
A-S Medication Solutions	SULFATRIM	sulfamethoxazole and trimethoprim	50090-7836	SILICA
Cycle Pharmaceuticals Ltd	PHYRAGO	dasatinib	70709-151	SILICA DIMETHYL SILYLATE

Generic drugs containing SILICA excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	indomethacin	50090-0050	SILICA
A-S Medication Solutions	indomethacin	50090-0051	SILICA
A-S Medication Solutions	indomethacin	50090-0054	SILICA

Silica Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 23, 2026

Silica is a critical multifunctional pharmaceutical excipient, but the market is fragmented across several material classes. The principal pharmaceutical grades are colloidal silicon dioxide, also called fumed silica; hydrated silica; precipitated silica; and mesoporous or porous silica used in specialized delivery systems. Demand is rising with solid-dose manufacturing, direct compression, continuous processing, and formulation work involving poorly soluble active pharmaceutical ingredients.

The market has attractive technical barriers but limited transparency. Public companies generally report silica within broader chemicals, health-care, or specialty-materials segments rather than as a standalone pharmaceutical-excipient business. Financial performance therefore depends on volume growth, grade mix, energy costs, capacity utilization, regulatory qualification, and long-term supply agreements rather than on a separately reported silica income statement.

What is pharmaceutical-grade silica used for?

Pharmaceutical silica is used mainly as a flow aid, adsorbent, anticaking agent, carrier, glidant, and processing aid.

Silica type	Principal pharmaceutical use	Typical commercial value
Colloidal silicon dioxide, fumed silica	Powder flow improvement, tablet manufacture, capsule filling	High-volume, qualified excipient
Hydrated silica	Adsorbent, carrier, abrasive, oral-care formulations	Moderate-volume, application-specific
Precipitated silica	Adsorbent and carrier systems	Lower pharmaceutical penetration than colloidal grades
Porous or mesoporous silica	Drug loading, controlled release, solubility enhancement	Low-volume, higher-value specialty segment
Silica aerogel and engineered porous silica	Delivery platforms and advanced formulation research	Niche, development-stage applications

Colloidal silicon dioxide is the largest pharmaceutical segment because small concentrations can materially improve powder handling. It is commonly used in tablets, hard capsules, multiparticulates, and oral powders. The material can reduce interparticle friction, improve flow through hoppers and feeders, and limit caking caused by moisture or electrostatic effects.

The excipient does not provide therapeutic activity. Its value comes from enabling consistent manufacturing and acceptable dosage-form performance.

How large is the pharmaceutical silica market?

No authoritative public database isolates global pharmaceutical silica revenue from broader fumed-silica, precipitated-silica, or specialty-excipient sales. Market-research estimates vary substantially because suppliers classify pharmaceutical silica differently.

A practical market view is:

• Pharmaceutical-grade silica is a small share of the global silica industry.
• Colloidal silicon dioxide accounts for most pharmaceutical volume.
• Pharmaceutical applications command higher prices than construction, tire, rubber, coatings, and industrial applications.
• Advanced porous silica has a much higher price per kilogram but remains small in commercial volume.
• Asia-Pacific is the fastest-growing demand region, while Europe and North America retain the highest concentration of established regulatory qualifications.

The broader precipitated and fumed silica industries are measured in billions of dollars globally, with demand led by tires, coatings, adhesives, food, cosmetics, and industrial applications. Pharmaceutical excipient applications represent a smaller but more defensible specialty segment because customer switching requires formulation testing, quality documentation, and regulatory review.

What are the main market growth drivers for pharmaceutical silica?

The strongest growth drivers are solid-dose volume, formulation complexity, and manufacturing efficiency.

Solid-dose manufacturing

Tablets and capsules remain the dominant pharmaceutical dosage forms. Silica is particularly valuable in formulations containing poorly flowing powders, low-dose active ingredients, hygroscopic excipients, or high drug loading.

Growth in generic drugs and contract manufacturing supports demand because manufacturers must achieve high throughput with consistent content uniformity and low tablet-weight variability.

Direct compression and continuous manufacturing

Direct compression reduces wet-granulation steps, drying requirements, and equipment intensity. It also increases the importance of powder flow and blend uniformity. Silica is often evaluated as part of a direct-compression excipient system.

Continuous manufacturing creates similar demand. Consistent powder feeding requires controlled particle size, density, surface area, moisture, and bulk behavior. Suppliers that can provide narrow specification ranges and lot-to-lot consistency have an advantage.

Poorly soluble active ingredients

Many development-stage compounds have low aqueous solubility. Porous silica can adsorb or host active ingredients and may improve dissolution or stabilize amorphous drug forms. These applications are technically attractive but face more demanding characterization and regulatory scrutiny than conventional glidant use.

Outsourced manufacturing

Contract development and manufacturing organizations increasingly support multiple dosage forms and customers. Standardized, globally accepted excipients reduce qualification costs across manufacturing sites. This favors established suppliers with multinational quality systems.

Emerging-market pharmaceutical production

India and China are expanding generic, complex-generic, and contract-manufacturing capacity. Local manufacturers increasingly use international pharmacopeial materials, but local silica producers also compete on price and lead time.

Which companies supply pharmaceutical silica?

The competitive market is concentrated among global specialty-materials producers and regional excipient suppliers.

Company	Relevant product families or capabilities	Competitive position
Evonik Industries	AEROSIL colloidal silicon dioxide; specialty drug-delivery materials	Strong global qualification base and advanced formulation capability
Cabot Corporation	CAB-O-SIL fumed silica and specialty silica	Large manufacturing footprint and broad industrial customer base
Wacker Chemie	HDK pyrogenic silica	Strong process control and global specialty-chemicals distribution
Grace	SYLOID and related silica products	Established pharmaceutical and food-processing applications
Fuji Silysia Chemical	SYLOID porous silica and specialty adsorbents	Strong position in porous silica and drug-delivery applications
Merck and regional distributors	Pharmaceutical excipient distribution and formulation support	Commercial access rather than primary silica production
Regional Chinese and Indian producers	Colloidal, precipitated, and specialty silica grades	Cost and geographic advantages, with variable global qualification depth

Evonik, Cabot, Wacker, Grace, and Fuji Silysia compete on more than price. Their differentiators include surface chemistry, particle morphology, specific surface area, moisture control, documentation, regulatory support, supply continuity, and technical service.

The market is less concentrated than the name-brand landscape suggests. Regional suppliers can compete successfully in standard grades, particularly where customers prioritize price and local inventory. Global suppliers retain an advantage in multinational projects and regulated markets.

How does silica pricing affect supplier profitability?

Silica profitability is sensitive to energy, raw materials, logistics, and grade mix.

Fumed silica production is energy intensive because it typically involves high-temperature hydrolysis processes. Changes in natural-gas, electricity, hydrogen, chlorosilane, and transport costs can affect margins. Pharmaceutical grades also require additional testing, controlled handling, documentation, and quality-system overhead.

The most important financial variables are:

1. Capacity utilization in specialty-silica plants.
2. The share of pharmaceutical and personal-care grades in total sales.
3. Contractual pass-through of energy and raw-material costs.
4. Freight costs for low-density material.
5. Qualification-related switching costs.
6. Demand from cyclical industrial end markets.

Pharmaceutical customers generally purchase smaller volumes than tire or coatings customers but accept higher prices when the material is qualified and technically important. This produces better revenue quality than commodity silica, although the segment remains exposed to customer inventory reductions and generic-drug pricing pressure.

What is the financial trajectory for pharmaceutical silica?

The likely financial trajectory is moderate volume growth with stronger value growth in specialized grades.

Base case

Standard colloidal silicon dioxide should track global solid-dose pharmaceutical production, generic-drug demand, and outsourcing growth. Revenue growth is likely to remain in the low- to mid-single digits over a normal cycle, with pricing influenced by energy and logistics.

Upside case

Higher growth would come from:

• Porous silica for solubility enhancement.
• Drug-loaded silica systems.
• Continuous manufacturing.
• High-dose and low-flow formulations.
• Global expansion of qualified excipient supply.
• Increased use of specialty grades with controlled surface chemistry.

These products can generate higher margins than standard glidants because customers buy formulation performance and regulatory support rather than only kilograms.

Downside case

A weaker trajectory would result from:

• Generic-drug price compression.
• Customer destocking.
• Excess industrial-silica capacity.
• Substitution with magnesium stearate, starch derivatives, colloidal cellulose, or formulation-specific flow aids.
• Regulatory restrictions affecting nano-scale material characterization.
• Delayed adoption of advanced silica delivery systems.

Public filings from major silica producers do not generally disclose pharmaceutical excipient revenue separately. Investors should therefore evaluate pharmaceutical silica through segment disclosures, product launches, capacity additions, pricing commentary, and healthcare-related specialty-materials results rather than through a standalone market capitalization or revenue line.

What regulatory status does pharmaceutical silica have?

The principal regulatory issue is not whether silica is used in pharmaceuticals, but whether the specific grade, particle characteristics, manufacturing process, and intended use are supported in the target jurisdiction.

United States

Colloidal silicon dioxide appears in the FDA Inactive Ingredient Database for multiple oral dosage forms. The database supports regulatory precedent but does not automatically approve every grade for every formulation. Sponsors must still demonstrate suitability, quality, safety, and compatibility in the drug product [1].

Pharmaceutical grades are typically supported by compendial specifications, including the United States Pharmacopeia-National Formulary, European Pharmacopoeia, or other recognized standards. FDA inactive-ingredient precedent is dosage-form and route specific.

Silica is not an active pharmaceutical ingredient and therefore does not have an Orange Book patent listing. The FDA Orange Book lists approved drug products and associated patents or exclusivity information, not independent excipient patents [2].

Europe

European suppliers commonly support compliance with the European Pharmacopoeia and applicable European Union excipient-quality requirements. Nanomaterial characterization, elemental impurities, residual substances, and particle-size distribution can receive attention during regulatory review.

Asia-Pacific

India, China, Japan, South Korea, and Australia use local regulatory requirements alongside recognized pharmacopeial standards. Global manufacturers generally prefer suppliers able to provide multi-compendial documentation and change-control commitments.

What patent protection covers pharmaceutical silica?

Conventional colloidal silicon dioxide is a mature material and generally has limited product-level patent protection. Commercial protection is more likely to arise from:

• Surface modification.
• Controlled particle morphology.
• Porosity and pore-size distribution.
• Drug-loading methods.
• Silica-lipid or silica-polymer composites.
• Controlled-release systems.
• Specific manufacturing processes.
• Formulations that use silica to stabilize amorphous active ingredients.

Patent risk is therefore concentrated in advanced delivery technologies rather than standard glidant applications. A patent covering a porous silica drug-delivery system may have commercial relevance even when the underlying silica is off patent.

Freedom-to-operate analysis should separate three layers:

Layer	Typical protection	Commercial risk
Base silica material	Mature composition and process technology	Low to moderate
Engineered silica grade	Surface chemistry, porosity, morphology	Moderate
Drug-product application	Drug loading, release, stabilization, formulation	Moderate to high

Paragraph IV challenges and Hatch-Waxman litigation generally concern the finished drug product, not the excipient itself. A silica supplier may become relevant in litigation if a product claim requires a particular silica grade or if the supplier provides technical evidence concerning formulation performance.

What manufacturing barriers protect pharmaceutical silica suppliers?

Manufacturing barriers are more important than patent barriers in standard pharmaceutical silica.

Key barriers include:

• High-temperature process equipment.
• Controlled particle-size and surface-area distribution.
• Low trace-metal levels.
• Consistent moisture content.
• Low bioburden and controlled packaging.
• Validated cleaning and change-control systems.
• Multi-site supply qualification.
• Regulatory documentation and audit readiness.
• Reliable global distribution of low-density materials.

Changing silica suppliers can require formulation trials, blend testing, tablet compression studies, dissolution testing, stability work, and regulatory documentation. The switching cost increases when silica is used in a narrow operating window or when a product has an established commercial process.

Supply interruptions remain a material risk because pharmaceutical manufacturers may qualify only one grade or one supplier. Dual sourcing reduces risk but can introduce performance differences caused by surface area, particle morphology, density, or moisture.

How does pharmaceutical silica compare with alternative excipients?

Excipient	Primary function	Advantage over silica	Limitation
Magnesium stearate	Lubrication	Effective and widely available	Excess use can impair dissolution and tablet strength
Colloidal cellulose	Binder and flow improvement	Multifunctional and compressible	May add bulk and alter disintegration
Starch derivatives	Binder, disintegrant, flow support	Broad formulation utility	Moisture and processing behavior vary
Calcium silicate	Adsorbent and carrier	Strong oil and liquid adsorption	Different compaction and density profile
Talc	Glidant and antiadherent	Low cost and established use	Regulatory and impurity considerations
Silica	Flow aid, adsorbent, carrier	Low use level and broad functionality	Dust handling and grade-specific performance

Silica has a strong position where a small addition can improve flow without materially increasing tablet mass. Its performance is highly grade dependent, so substitution is possible but rarely automatic.

What generic launch and commercial risks exist?

Generic manufacturers face relatively low direct patent risk from standard silica. The main risks are operational and regulatory:

• A qualified grade may be unavailable.
• An alternative supplier may change dissolution or tablet hardness.
• Material variability may affect content uniformity.
• A new grade may require stability or comparability work.
• Fine-particle dust may increase occupational-control requirements.
• Advanced silica delivery systems may be protected by application patents.

For branded products, the excipient can support formulation differentiation even when the base drug is no longer patent protected. A formulation patent that claims a specific silica grade, particle size, loading ratio, or stabilization method can delay generic substitution if the claim survives validity and infringement challenges.

What should investors monitor in the silica excipient market?

The most useful indicators are:

1. Pharmaceutical and generic tablet volumes.
2. Capacity additions for fumed and specialty silica.
3. Energy and chlorosilane cost trends.
4. Supplier price increases and surcharge activity.
5. Qualification of Chinese and Indian manufacturers.
6. Demand for porous silica drug-delivery platforms.
7. FDA and European scrutiny of nano-scale materials.
8. Contract-manufacturing expansion.
9. Inventory levels among pharmaceutical customers.
10. Mix shift from commodity to pharmaceutical and advanced grades.

The best-positioned suppliers are likely to be those with pharmaceutical documentation, strong technical support, multi-region manufacturing, and a portfolio that spans conventional excipients and advanced delivery materials.

Key Takeaways

• Pharmaceutical silica is led by colloidal silicon dioxide used as a glidant, adsorbent, carrier, and processing aid.
• The market is smaller than the broader silica industry but has higher qualification barriers and better pricing than commodity applications.
• Standard silica has limited product-patent protection; manufacturing capability, quality systems, and customer qualification are the primary barriers.
• Porous and engineered silica offers the strongest growth and margin opportunity, but adoption is slower because regulatory and formulation requirements are more demanding.
• Public companies do not generally report pharmaceutical silica revenue separately.
• Demand should grow with solid-dose production, direct compression, continuous manufacturing, and poorly soluble drug development.
• Main risks are energy costs, industrial-cycle exposure, generic-drug pricing pressure, customer destocking, and regulatory scrutiny of engineered or nano-scale materials.
• Orange Book, Paragraph IV, and biosimilar frameworks do not directly apply to silica as an excipient. They become relevant only through the finished drug product using the material.

FAQs

Is colloidal silicon dioxide the same as silica excipient?

Colloidal silicon dioxide is one pharmaceutical form of silica. Pharmaceutical silica also includes hydrated, precipitated, porous, and engineered grades with different properties and uses.

Does silica have an FDA-approved drug status?

Silica is an inactive ingredient, not an active drug. Specific grades have regulatory precedent through FDA inactive-ingredient records and pharmacopeial specifications, but each finished product requires its own quality and formulation assessment.

Can pharmaceutical manufacturers replace one silica supplier with another?

Yes, but substitution usually requires comparative testing because surface area, particle morphology, moisture, density, and flow performance can differ materially between suppliers.

Is pharmaceutical silica exposed to biosimilar competition?

No direct biosimilar competition exists for silica. Biosimilar manufacturers may use silica-containing formulations or processes, but the regulatory and commercial competition concerns the biologic product, not the excipient itself.

Which silica applications have the highest growth potential?

Porous silica, drug-loading systems, amorphous-solid stabilization, controlled release, and solubility-enhancement technologies have higher growth potential than conventional glidant applications.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Colloidal silicon dioxide monograph. Rockville, MD: United States Pharmacopeial Convention.

4. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Strasbourg, France: Council of Europe.

5. European Food Safety Authority. (2024). Re-evaluation of silicon dioxide, including nanoparticles, as a food additive. EFSA Journal.

6. Evonik Industries AG. (2024). Annual report 2023. Essen, Germany: Evonik Industries AG.

7. Cabot Corporation. (2024). Annual report 2023. Boston, MA: Cabot Corporation.

8. Wacker Chemie AG. (2024). Annual report 2023. Munich, Germany: Wacker Chemie AG.

9. Grace. (2024). Pharmaceutical excipients and drug-delivery materials product information. Columbia, MD: W. R. Grace & Co.

10. Fuji Silysia Chemical Ltd. (2024). Pharmaceutical-grade porous silica product information. Kasugai, Japan: Fuji Silysia Chemical Ltd.